Cargando…

Effectiveness of whole exome sequencing in unsolved patients with a clinical suspicion of a mitochondrial disorder in Estonia

OBJECTIVE: Reaching a genetic diagnosis of mitochondrial disorders (MDs) is challenging due to their broad phenotypic and genotypic heterogeneity. However, there is growing evidence that the use of whole exome sequencing (WES) for diagnosing patients with a clinical suspicion of an MD is effective (...

Descripción completa

Detalles Bibliográficos
Autores principales: Puusepp, Sanna, Reinson, Karit, Pajusalu, Sander, Murumets, Ülle, Õiglane-Shlik, Eve, Rein, Reet, Talvik, Inga, Rodenburg, Richard J., Õunap, Katrin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6043467/
https://www.ncbi.nlm.nih.gov/pubmed/30009132
http://dx.doi.org/10.1016/j.ymgmr.2018.03.004
_version_ 1783339288342036480
author Puusepp, Sanna
Reinson, Karit
Pajusalu, Sander
Murumets, Ülle
Õiglane-Shlik, Eve
Rein, Reet
Talvik, Inga
Rodenburg, Richard J.
Õunap, Katrin
author_facet Puusepp, Sanna
Reinson, Karit
Pajusalu, Sander
Murumets, Ülle
Õiglane-Shlik, Eve
Rein, Reet
Talvik, Inga
Rodenburg, Richard J.
Õunap, Katrin
author_sort Puusepp, Sanna
collection PubMed
description OBJECTIVE: Reaching a genetic diagnosis of mitochondrial disorders (MDs) is challenging due to their broad phenotypic and genotypic heterogeneity. However, there is growing evidence that the use of whole exome sequencing (WES) for diagnosing patients with a clinical suspicion of an MD is effective (39–60%). We aimed to study the effectiveness of WES in clinical practice in Estonia, in patients with an unsolved, but suspected MD. We also show our first results of mtDNA analysis obtained from standard WES reads. METHODS: Retrospective cases were selected from a database of 181 patients whose fibroblast cell cultures had been stored from 2003 to 2013. Prospective cases were selected during the period of 2014–2016 from patients referred to a clinical geneticist in whom an MD was suspected. We scored each patient according to the mitochondrial disease criteria (MDC) (Morava et al., 2006) after re-evaluation of their clinical data, and then performed WES analysis. RESULTS: A total of 28 patients were selected to the study group. A disease-causing variant was found in 16 patients (57%) using WES. An MD was diagnosed in four patients (14%), with variants in the SLC25A4, POLG, SPATA5, and NDUFB11 genes. Other variants found were associated with a neuromuscular disease (SMN1, MYH2, and LMNA genes), neurodegenerative disorder (TSPOAP1, CACNA1A, ALS2, and SCN2A genes), multisystemic disease (EPG5, NKX1–2, ATRX, and ABCC6 genes), and one in an isolated cardiomyopathy causing gene (MYBPC3). The mtDNA point mutation was found in the MT-ATP6 gene of one patient upon mtDNA analysis. CONCLUSIONS: The diagnostic yield of WES in our cohort was 57%, proving to be a very good effectiveness. However, MDs were found in only 14% of the patients. We suggest WES analysis as a first-tier method in clinical genetic practice for children with any multisystem, neurological, and/or neuromuscular problem, as nuclear DNA variants are more common in children with MDs; a large number of patients harbor disease-causing variants in genes other than the mitochondria-related ones, and the clinical presentation might not always point towards an MD. We have also successfully conducted analysis of mtDNA from standard WES reads, providing further evidence that this method could be routinely used in the future.
format Online
Article
Text
id pubmed-6043467
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-60434672018-07-13 Effectiveness of whole exome sequencing in unsolved patients with a clinical suspicion of a mitochondrial disorder in Estonia Puusepp, Sanna Reinson, Karit Pajusalu, Sander Murumets, Ülle Õiglane-Shlik, Eve Rein, Reet Talvik, Inga Rodenburg, Richard J. Õunap, Katrin Mol Genet Metab Rep Research Paper OBJECTIVE: Reaching a genetic diagnosis of mitochondrial disorders (MDs) is challenging due to their broad phenotypic and genotypic heterogeneity. However, there is growing evidence that the use of whole exome sequencing (WES) for diagnosing patients with a clinical suspicion of an MD is effective (39–60%). We aimed to study the effectiveness of WES in clinical practice in Estonia, in patients with an unsolved, but suspected MD. We also show our first results of mtDNA analysis obtained from standard WES reads. METHODS: Retrospective cases were selected from a database of 181 patients whose fibroblast cell cultures had been stored from 2003 to 2013. Prospective cases were selected during the period of 2014–2016 from patients referred to a clinical geneticist in whom an MD was suspected. We scored each patient according to the mitochondrial disease criteria (MDC) (Morava et al., 2006) after re-evaluation of their clinical data, and then performed WES analysis. RESULTS: A total of 28 patients were selected to the study group. A disease-causing variant was found in 16 patients (57%) using WES. An MD was diagnosed in four patients (14%), with variants in the SLC25A4, POLG, SPATA5, and NDUFB11 genes. Other variants found were associated with a neuromuscular disease (SMN1, MYH2, and LMNA genes), neurodegenerative disorder (TSPOAP1, CACNA1A, ALS2, and SCN2A genes), multisystemic disease (EPG5, NKX1–2, ATRX, and ABCC6 genes), and one in an isolated cardiomyopathy causing gene (MYBPC3). The mtDNA point mutation was found in the MT-ATP6 gene of one patient upon mtDNA analysis. CONCLUSIONS: The diagnostic yield of WES in our cohort was 57%, proving to be a very good effectiveness. However, MDs were found in only 14% of the patients. We suggest WES analysis as a first-tier method in clinical genetic practice for children with any multisystem, neurological, and/or neuromuscular problem, as nuclear DNA variants are more common in children with MDs; a large number of patients harbor disease-causing variants in genes other than the mitochondria-related ones, and the clinical presentation might not always point towards an MD. We have also successfully conducted analysis of mtDNA from standard WES reads, providing further evidence that this method could be routinely used in the future. Elsevier 2018-03-15 /pmc/articles/PMC6043467/ /pubmed/30009132 http://dx.doi.org/10.1016/j.ymgmr.2018.03.004 Text en © 2018 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Research Paper
Puusepp, Sanna
Reinson, Karit
Pajusalu, Sander
Murumets, Ülle
Õiglane-Shlik, Eve
Rein, Reet
Talvik, Inga
Rodenburg, Richard J.
Õunap, Katrin
Effectiveness of whole exome sequencing in unsolved patients with a clinical suspicion of a mitochondrial disorder in Estonia
title Effectiveness of whole exome sequencing in unsolved patients with a clinical suspicion of a mitochondrial disorder in Estonia
title_full Effectiveness of whole exome sequencing in unsolved patients with a clinical suspicion of a mitochondrial disorder in Estonia
title_fullStr Effectiveness of whole exome sequencing in unsolved patients with a clinical suspicion of a mitochondrial disorder in Estonia
title_full_unstemmed Effectiveness of whole exome sequencing in unsolved patients with a clinical suspicion of a mitochondrial disorder in Estonia
title_short Effectiveness of whole exome sequencing in unsolved patients with a clinical suspicion of a mitochondrial disorder in Estonia
title_sort effectiveness of whole exome sequencing in unsolved patients with a clinical suspicion of a mitochondrial disorder in estonia
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6043467/
https://www.ncbi.nlm.nih.gov/pubmed/30009132
http://dx.doi.org/10.1016/j.ymgmr.2018.03.004
work_keys_str_mv AT puuseppsanna effectivenessofwholeexomesequencinginunsolvedpatientswithaclinicalsuspicionofamitochondrialdisorderinestonia
AT reinsonkarit effectivenessofwholeexomesequencinginunsolvedpatientswithaclinicalsuspicionofamitochondrialdisorderinestonia
AT pajusalusander effectivenessofwholeexomesequencinginunsolvedpatientswithaclinicalsuspicionofamitochondrialdisorderinestonia
AT murumetsulle effectivenessofwholeexomesequencinginunsolvedpatientswithaclinicalsuspicionofamitochondrialdisorderinestonia
AT oiglaneshlikeve effectivenessofwholeexomesequencinginunsolvedpatientswithaclinicalsuspicionofamitochondrialdisorderinestonia
AT reinreet effectivenessofwholeexomesequencinginunsolvedpatientswithaclinicalsuspicionofamitochondrialdisorderinestonia
AT talvikinga effectivenessofwholeexomesequencinginunsolvedpatientswithaclinicalsuspicionofamitochondrialdisorderinestonia
AT rodenburgrichardj effectivenessofwholeexomesequencinginunsolvedpatientswithaclinicalsuspicionofamitochondrialdisorderinestonia
AT ounapkatrin effectivenessofwholeexomesequencinginunsolvedpatientswithaclinicalsuspicionofamitochondrialdisorderinestonia